Sernova Biotherapeutics (FRA:PSH0) EPS (Basic): €-0.02 (TTM As of Apr. 2026)


FRA:PSH0 Sernova Biotherapeutics Inc FRA:PSH0
27 GF Score
Price €0.09
! 2 Warning Signs
View Full Analysis

What is Sernova Biotherapeutics EPS (Basic)?

Sernova Biotherapeutics FRA:PSH0 -6.00% 27 EPS (Basic) is €-0.02 as of Apr. 2026. GuruFocus rates FRA:PSH0 with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

Sernova Biotherapeutics's basic earnings per share (Basic EPS) for the three months ended in Apr. 2026 was €-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Apr. 2026 was €-0.02.

Sernova Biotherapeutics's EPS (Diluted) for the three months ended in Apr. 2026 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was €-0.02.

Sernova Biotherapeutics's EPS without NRI for the three months ended in Apr. 2026 was €-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Apr. 2026 was -0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Sernova Biotherapeutics  (FRA:PSH0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sernova Biotherapeutics EPS (Basic) Related Terms

Sernova Biotherapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Sernova Biotherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sernova Biotherapeutics EPS (Basic) Chart

Sernova Biotherapeutics Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.07 -0.09 -0.07 -0.03

Sernova Biotherapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01
FRA:PSH0
27GF Score
Sernova Biotherapeutics Inc FRA:PSH0
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sernova Biotherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sernova Biotherapeutics's Basic EPS for the fiscal year that ended in Oct. 2025 is calculated as

Basic EPS (A: Oct. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-9.668-0)/328.287
=-0.03

Sernova Biotherapeutics's Basic EPS for the quarter that ended in Apr. 2026 is calculated as

Basic EPS (Q: Apr. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.007-0)/351.117
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.02 mean?
Sernova Biotherapeutics (FRA:PSH0) has a EPS (Basic) of €-0.02 as of Apr. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sernova Biotherapeutics and its competitors.
Is Sernova Biotherapeutics' EPS (Basic) too high?
Sernova Biotherapeutics' current EPS (Basic) is €-0.02. Overall, Sernova Biotherapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Sernova Biotherapeutics' EPS (Basic) compare to VRTX and REGN?
Sernova Biotherapeutics' EPS (Basic) of €-0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sernova Biotherapeutics and its competitors. Sernova Biotherapeutics's current EPS (Basic) is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sernova Biotherapeutics stock overvalued right now?
Sernova Biotherapeutics (FRA:PSH0) has a current EPS (Basic) of €-0.02. The current EPS (Basic) is €-0.02. Sernova Biotherapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Sernova Biotherapeutics (FRA:PSH0), the current EPS (Basic) is €-0.02 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sernova Biotherapeutics Business Description

Other Exchanges SEOVF:USASVA:Canada
Address RPO Central Parkway, PO Box 29592, Mississauga, ON, CAN, L5A 4H2
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
27GF Score

Get the complete analysis for FRA:PSH0

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price